The term CDMO (contract development and manufacturing organisation) has become ubiquitous in the pharmaceutical industry over the past decade, perhaps even reaching the heights of “buzzword”. But does it represents a paradigm change in how drugs are developed and manufactured?
Evaluate brought together senior executives from both chemical and biological CDMOs to discuss the key issues in this space. In this article, Dr Andrew Warmington reports back on the drivers of this shift, the opportunities and challenges for its key players, and the outlook for the coming years. We ask:
- How has biotech innovation helped shape the evolution of the CDMO?
- Will the Biosecure Act is deliver greater opportunities to India?
- Is consolidation set to change the CDMO landscape?
- How can CDMOs navigate growing complexity across large site networks and new modalities?
